Revenio Group saw the highest growth of 3.99% in patent filings in April and 1.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 3.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Revenio Group‘s patent filings and grants. Buy the databook here.
Revenio Group has been focused on protecting inventions in China(CN) with two publications in Q2 2024
The China(CN) Patent Office dominates the patent filings and grants with nearly 17% filings and 33% grants. The Finland(FI), World Intellectual Property Organization(WIPO), China(CN), and European Patent Office(EPO) patent Office are among the top ten patent offices where Revenio Group is filings its patents. Among the top granted patent authorities, Revenio Group has 33% of its grants in China(CN) and 33% in Spain(ES).
Equinox Ophthalmic could be the strongest competitor for Revenio Group
In terms of grant share, Revenio Group stands first among its competitors followed by Revenio Group and Equinox Ophthalmic.
Patents related to healthtech and connected patient lead Revenio Group's portfolio
Revenio Group has the highest number of patents in healthtech followed by, connected patient. For healthtech, nearly 50% of patents were filed and no patents were granted in Q2 2024.
Ophthalmic devices related patents lead Revenio Group portfolio followed by diagnostic imaging, and tonometers
Revenio Group has highest number of patents in ophthalmic devices followed by diagnostic imaging, tonometers. For ophthalmic devices, nearly 67% of patents were filed and 100% of patents were granted in Q2 2024.
For comprehensive analysis of Revenio Group's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.